REMARKS

Claims 1-20 have been cancelled and new claims 21-26 have been added. Claims 21-26 are currently pending in the application.

Amendments to the specification correct typographical errors and expressly incorporate material from earlier applications whose specifications were incorporated by reference.

In particular, the following amendment have been made:

- (1) The title has been amended to better reflect the subject matter of the pending claims.
- (2) On page 4 and 8, passages were expressly incorporated from the prior application USSN 09/698,846 (that was incorporated by reference in the instant application, see page 1, lines 7-8). This prior application has since issued as U.S. patent 6,627,400.
- (3) On page 61, old Tables 5 and 6 were replaced by new Table 5 that was expressly incorporated from the great-grandparent application USSN 09/602,586 (again, this application was incorporated by reference in the instant application). New Table 5 has been amended to add SEQ ID numbers in the right-most column.
- (4) The passage inserted on page 4 and new Table 5 include corrections to typographical errors and the addition of SEQ ID numbers, respectively.
- (5) Corrections to the figure captions for Figures 4, 33, and 34 have been made to correct typographical errors.
 - (6) A Sequence Listing has been added.

The subject matter of the above claims roughly corresponds to that of allowed claims 30-36 of parent application USSN 09/825,244 ('244).

Basis* new claims are as follows:

New Claim(s)	Term/Phrase	Basis	
21	"composition"	Page 12, line 41, to page 14, line 39.	
21	"aggregation of proteins"	Page 32, lines 28-31.	(19.4.6)
-		Page 17, line 3.	('846)
21	"set of electrophoretic probes"	Page 4, lines 10-11. Page 10, lines 35-41.	
21	"electrophoretic probe"	Page 10, lines 11-34.	
21	"second reagent generating an	Page 14, lines 4-5.	
	active species to cleave the cleavable linkage"	Page 18, lines 22-29.	('846)

21	"I(D M) I] T"	Claim 1	
41	"[(D, M)-L] _k -T"	Claim 1	
21	"k 1 to 20"	Page 30, line 45.	
21	"K 1 to 20"	Page 30, line 45.	
		Page 33, Table 4.	(10.46)
	64	Page 18, lines 7-8.	('846)
21	"target-binding moiety"	Page 8, line 34;	
-01	11 1 11 11 11	Page 32, lines 20-21.	
21	"cleavable linkage"	Claim 1	
		Page 20, line 8, to page 22, line 27.	('846)
21	"comprising a detection group, D, and a mobility modifier, M,"	Page 4, lines 21-25.	
21	"eTag reporter with a unique	Page 8, line 37.	
	electrophoretic mobility"	Page 8, line 45.	
21	Different "eTag reporters form	Claim 1 (lines 21-22)	
	distinct peaks upon electrophoretic	Page 4, lines 21-23.	
	separation."	Figs. 5, 6, & 8	
	•	Page 8, lines 12-13.	('846)
		Figs. 7	('846)
22	"1 to 500 atoms" in reference to M	Page 18, line 6.	
22	"group consisting of carbon,	Page 18, lines 8-9.	
	hydrogen, oxygen, nitrogen, sulfur,	Figs. 1C, 5, 6, 15, 17A-J.	
	phosphorus, and boron" in reference		
	to M		
23	"cleavable linkage is selected from the	Page 19, lines 10-14.	('846)
	group consisting of olefins, thioethers,	Pages 21-22.	('846)
	sulfoxides, and selenium analogs of		, ,
	thioethers or sulfoxides"		
23, 27	"active species selected from the	Page 18, lines 26-27.	('846)
	group consisting of singlet oxygen,		
	hydrogen peroxide, NADH, and		
	hydrogen radicals."		
24, 28	"detection group is a fluorophore, a	Claim 17.	
	chromophore, or an electrochemical		
	label "		
25, 29	"antibody binding compound is a	Page 14, lines 27-39.	
·	monoclonal antibody or a polyclonal		
	antibody"		
30	"sensitizer capable of generating	Claim 7	
	singlet oxygen when photoactivated"	Page 33, Table 3 and Table 4, in column	
	1 2 7,8 11-1	entitled "e-tag Release"	·
		Page 20, lines 8-22.	('846)
27	"cleavable linkage is a disulfide bond"	Claim 6	_ (0.0)
29	"k is in the range of from 1 to 3"	Page 31, line 5.	
20	61.	<u> </u>	
30	"distinct charge/mass ratio in the range	Page 24, line 7-14.	
20	of from -0.001 to 0.5"		
_30	"a fluorescein"	Fig. 5	

* Whenever basis for a term or phrase of the new claims is found in the incorporated passages, the page and line numbers refer to the location in the grandparent application 09/698,846. (Such page and line references have the designation "('846)" in the right hand side of the box below).

No new matter has been added by the amendments.

If any additional time extensions are required, such time extensions are hereby requested. If any additional fees not submitted with this response are required, please take such fees from deposit account 50-2266.

Respectfully submitted,

Stephen C. Macevicz Reg. No. 30,285

Attorney for Applicants

Telephone: (650) 210-1223

Email: smacevicz@aclara.com

Enclosures:

Information Disclosure Statement
Declaration of Sequence Listing
3.5 inc diskette Text File of Sequence Listing